CompletedPhase 4

IPACK Nerve Block for Total Knee Arthroplasty

72 participantsStarted 2016-11-17

Plain-language summary

Double-blind, randomized controlled clinical trial to test the efficacy of IPACK on postoperative opioid consumption, patient satisfaction, pain scores, mobility, and several other secondary outcomes in adults undergoing primary unilateral TKA. Enrolled patients will be randomized to either continuous ACB with IPACK or to continuous ACB with sham subcutaneous saline injection. Outcomes assessors and patients will be blinded to the intervention.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Unilateral, primary tricompartment total knee arthroplasty * Age 18 years or older * ASA I-III * Eligible for spinal or combined spinal epidural anesthetic * Able to speak, read, and understand English * Willing to participate in the trial Exclusion Criteria: * Contraindication to regional anesthesia or peripheral nerve blocks * Allergy to local anesthetics * Allergy to NSAIDs * Chronic renal insufficiency with Cr \> 1.4 or GFR \< 60 * Have chronic pain that is not related to their knee joint * Have been using opioids on a chronic basis (daily or almost daily opioid use for 3 months or longer) * Have a pre-existing peripheral neuropathy involving the operative site * Body mass index greater than or equal to 40

What they're measuring

Cumulative opioid consumption (morphine equivalents) in the first 24 hours

Timeframe: 24 hours

Trial details

NCT IDNCT03921034

SponsorOchsner Health System

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-01-23

View on ClinicalTrials.gov More Arthropathy of Knee trials